AZD4956
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 04, 2026
PARTHENON: Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
(clinicaltrials.gov)
- P1/2 | N=180 | Not yet recruiting | Sponsor: AstraZeneca
Monotherapy • New P1/2 trial • Breast Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1